C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the addition of William McKee and Jolie M. Siegel to its leadership team as Chief Financial Officer and Chief Legal Officer, respectively.Mr. McKee currently also serves as Chief Executive Officer of MBJC Associates, LLC, a business consulting firm serving the pharmaceutical and biotech industry. Mr. McKee served as Chief Operating Officer and Chief Financial Officer for EKR Therapeutics, Inc. from July 2010 until June 2012 when EKR was sold to Cornerstone Therapeutics Inc. Until March 2010, Mr. McKee served as the Executive Vice President, Chief Financial Officer and Treasurer of Barr Pharmaceuticals, LLC, a subsidiary of Teva Pharmaceutical Industries Limited. Mr. McKee was also Executive Vice President and Chief Financial Officer of Barr from 1996 until its acquis
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024GlobeNewswire
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $107.00 price target on the stock.MarketBeat
- Fragmented Europe to make new bid for US-style capital market [Reuters]Reuters
- Pfizer wins pause on Moderna's COVID-19 patent lawsuit [Reuters]Reuters
- Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1' immune cell engager CB699 at AACR 2024 [Yahoo! Finance]Yahoo! Finance
BNTX
Earnings
- 3/20/24 - Miss
BNTX
Sec Filings
- 4/8/24 - Form 6-K
- 4/8/24 - Form 6-K
- 3/25/24 - Form 6-K
- BNTX's page on the SEC website